VIRX - Viracta Therapeutics Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

3.814M

Cash

39.57M

Avg Qtr Burn

-9.10M

Short % of Float

3.95%

Insider Ownership

2.76%

Institutional Own.

49.92%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Nana-val (nanatinostat + valganciclovir) Details Lymphoma, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nana-val (Nanatinostat (VRx-3996) (histone deacetylase (HDAC) inhibitor) + valganciclovir) Details Solid tumor/s, Cancer, Nasopharyngeal carcinoma	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.